Ramipril Capsule
NDC Package 51655-346-26

11-digit billing NDC: 51655034626

Package Information

Ramipril capsules is indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. This formulation utilizes a capsule delivery system. Marketed by Northwind Health Company, Llc, this product is identified by NDC 51655-346 and is authorized under FDA application ANDA077626.

Identification & Billing

NDC Package Code
51655-346-26
Package Description
90 CAPSULE in 1 BOTTLE, PLASTIC
Product Code
11-Digit Billing Format
51655034626
RxNorm Crosswalk
RxCUI: 261962 - ramipril 10 MG Oral Capsule

Clinical Specifications

Proprietary Name
Ramipril
Non-Proprietary Name
Ramipril
Substance Name
Ramipril
Dosage Form
Capsule - A solid oral dosage form consisting of a shell and a filling. The shell is composed of a single sealed enclosure, or two halves that fit together and which are sometimes sealed with a band. Capsule shells may be made from gelatin, starch, or cellulose, or other suitable materials, may be soft or hard, and are filled with solid or liquid ingredients that can be poured or squeezed.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Ramipril capsules is indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. Ramipril capsules can be used in addition to other needed treatment (such as antihypertensive, antiplatelet, or lipid-lowering therapy ) [see CLINICAL STUDIES ( 14.2)]. . Initiate dosing at 2.5 mg once daily for 1 week, 5 mg once daily for the next 3 weeks, and then increase as tolerated, to a maintenance dose of 10 mg once daily. If the patient is hypertensive or recently post-myocardial infarction, ramipril capsule can also be given as a divided dose.. The HOPE study was a large, multicenter, randomized, double-blind, placebo-controlled, 2 x 2 factorial design study conducted in 9541 patients (4645 on ramipril) who were 55 years or older and considered at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that was accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria). Patients were either normotensive or under treatment with other antihypertensive agents. Patients were excluded if they had clinical heart failure or were known to have a low ejection fraction (<0.40). This study was designed to examine the long-term (mean of 5 years) effects of ramipril (10 mg orally once daily) on the combined endpoint of myocardial infarction, stroke, or death from cardiovascular causes.The HOPE study results showed that ramipril (10 mg/day) significantly reduced the rate of myocardial infarction, stroke, or death from cardiovascular causes (826/4652 vs. 651/4645, relative risk 0.78), as well as the rates of the 3 components of the combined endpoint. The relative risk of the composite outcomes in the ramipril group as compared to the placebo group was 0.78% (95% confidence interval, 0.70–0.86). The effect was evident after about 1 year of treatment.Table 3. Summary of Combined Components and Endpoints—HOPE StudyOutcomePlacebo(N=4652) n (%)Ramipril(N=4645)n (%)Relative Risk(95% CI)P-ValueCombined EndpointMyocardial infarction, stroke, or death from cardiovascular cause 826 (17.8%) 651 (14.0%) 0.78 (0.70–0.86) P=0.0001 Component EndpointDeath from cardiovascular causes 377 (8.1%) 282 (6.1%) 0.74 (0.64–0.87) P=0.0002 Myocardial infarction 570 (12.3%) 459 (9.9%) 0.80 (0.70–0.90) P=0.0003 Stroke 226 (4.9%) 156 (3.4%) 0.68 (0.56–0.84) P=0.0002 Overall MortalityDeath from any cause 569 (12.2%) 482 (10.4%) 0.84 (0.75–0.95) P=0.005 Figure 1. Kaplan-Meier Estimates of the Composite Outcome of Myocardial Infarction, Stroke, or Death from Cardiovascular Causes in the Ramipril Group and the Placebo GroupRamipril was effective in different demographic subgroups (i.e., gender, age), subgroups defined by underlying disease (e.g., cardiovascular disease, hypertension), and subgroups defined by concomitant medication. There were insufficient data to determine whether or not ramipril was equally effective in ethnic subgroups.This study was designed with a prespecified substudy in diabetics with at least one other cardiovascular risk factor. Effects of ramipril on the combined endpoint and its components were similar in diabetics (N=3577) to those in the overall study population.Table 4. Summary of Combined Endpoints and Components in Diabetics—HOPE StudyOutcomePlacebo(N=1769)n (%)Ramipril (N=1808)n (%)Relative Risk Reduction(95% CI)P-ValueCombined EndpointMyocardial infarction, stroke, or death from cardiovascular cause 351 (19.8%) 277 (15.3%) 0.25 (0.12–0.36) P=0.0004 Component EndpointDeath from cardiovascular causes 172 (9.7%) 112 (6.2%) 0.37 (0.21–0.51) P=0.0001 Myocardial infarction 229 (12.9%) 185 (10.2%) 0.22 (0.06–0.36) P=0.01 Stroke 108 (6.1%) 76 (4.2%) 0.33 (0.10–0.50) P=0.007 Figure 2. The Beneficial Effect of Treatment with Ramipril on the Composite Outcome of Myocardial Infarction, Stroke, or Death from Cardiovascular Causes Overall and in Various SubgroupsCerebrovascular disease was defined as stroke or transient ischemic attacks. The size of each symbol is proportional to the number of patients in each group. The dashed line indicates overall relative risk.The benefits of Ramipril were observed among patients who were taking aspirin or other antiplatelet agents, beta- blockers, and lipid-lowering agents as well as diuretics and calcium channel blockers.

Regulatory & Marketing

Labeler Name
Northwind Health Company, Llc
Product Type
Human Prescription Drug
FDA Application #
ANDA077626
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
05-27-2020
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (51655-346). Click a package code to view its specific billing and regulatory data.

30 CAPSULE in 1 BOTTLE, PLASTIC

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 51655-346-26 identifies a specific commercial package of 90 capsule in 1 bottle, plastic of Ramipril, a human prescription drug labeled by Northwind Health Company, Llc. This capsule is formulated for oral use and contains ramipril as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Northwind Health Company, Llc on May 27, 2020. The current certification is valid through December 31, 2027.

How is this Northwind Health Company, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 51655034626. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
51655-346-26
11-Digit CMS (5-4-2)
51655-0346-26

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.